Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type
- 757 Downloads
There is growing need for a reliable assay for measuring fibroblast growth factor 23 (FGF23), a regulator of phosphorus and vitamin D. In this work, we analyze and compare the performance of three available assays, including the effect of temperature and time. This knowledge will allow for better understanding of FGF23 in the future.
Intact and C-terminal FGF23 (iFGF23 and cFGF23) concentrations are important in the diagnosis of hypo- and hyperphosphatemic diseases. The effects of temperature, storage, and specimen handling on FGF23 levels are not well known. We investigated the effects of various factors on plasma and serum measurement of FGF23 using three different assays.
Serum and plasma FGF23 were measured using three commercially available ELISA assays—two measuring iFGF23 and one measuring cFGF23. Samples from subjects with known FGF23 disorders were stored at 4, 22, and 37 °C and analyzed at different intervals up to 48 hours (h). A subset of samples underwent repeated freeze-thaw cycles, and samples frozen at −80 °C for up to 60 months were reanalyzed. The effect of adding a furin convertase inhibitor on FGF23 degradation was investigated using samples stored at 37 °C for 48 h. Intact FGF23 levels were measured from plasma samples of four different groups to test the correlation of the two assays.
Plasma FGF23 levels were stable when stored at 4 and 22 °C for 48 h. Both plasma and serum FGF23 levels demonstrated relative stability after five freeze-thaw cycles. Long-term storage at −80 °C for 40 months induced some variability in FGF23 levels. The addition of a furin inhibitor did not affect FGF23 degradation. Intact FGF23 levels showed good correlation only at the upper limit of the assay range when comparing the two assays.
Sample type, handling, and choice of assay are factors that affect FGF23 levels and should be considered when measuring this hormone.
KeywordsAssay FGF23 Immutopics Kainos Stability
Compliance with ethical standards
The study was approved by the National Institute of Dental and Craniofacial Research Institutional Review Board, and all subjects provided written informed consent, in accordance with NIH regulations.
Conflicts of interest
This study was supported by the Division of Intramural Research, National Institute of Dental and Craniofacial Research, and the National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD.
- 1.(2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348Google Scholar
- 8.Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578–585CrossRefPubMedGoogle Scholar
- 11.Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H (2006) Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370–18377CrossRefPubMedGoogle Scholar
- 13.Laboratories K FGF23 Elisa Kit. Kainos Laboratories. https://urldefense.proofpoint.com/v2/url?u=http-3A__www.kainos.co.jp_eng_products_fgf23-5Fe_fgf23-5Fe-5F5.html&d=CwIGaQ&c=y2w-uYmhgFWijp_IQN0DhA&r=DJVe1wVKJMh0si5z45T_YA&m=1G-SyHxhJ_fo6HMj693ilXk2lHraj_k71CpC9OH-9fo&s=Ru227ES1F_DD1IecUNPANWS47SCgjkC5DkAjOGRLQM8&e= 2015
- 14.International I FGF23 C-terminal and Intact Immutopics. http://www.immutopics.com 2015
- 15.Shrivastava A GV (2011) Methods for the determination of limit of detection and limit of quantitation of the analytical methods. Chron Young Sci 21–25Google Scholar
- 19.Heins M, Heil W, Withold W (1995) Storage of serum or whole blood samples? Effects of time and temperature on 22 serum analytes. Eur J Clin Chem Clin Biochem: J Forum Eur Clin Chem Soc 33:231–238Google Scholar
- 22.Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B (2004) Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol: J Int Soc Matrix Biol 23:421–432CrossRefGoogle Scholar